Aditxt, Inc.

ADTX · NASDAQ

Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun the capital structure.

Follow Add to Watchlist Ask Question

NASDAQ ADTX Coverage Bootstrap Biotechnology Diagnostics Going Concern

Latest ReportMay 14, 2026Aditxt: The Biotech Roll-Up Fighting Nasdaq Before It Fights DiseaseView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.